• Respiforb 80 mcg + 4.5 mcg/dose: Indicated for asthma management, including symptom prevention and relief, and reducing exacerbation risks.
• Respiforb 160 mcg + 4.5 mcg/dose: Indicated for asthma management, including symptom prevention and relief, and reducing exacerbation risks. Suitable for any asthma severity requiring inhaled glucocorticoids; also for symptomatic therapy in COPD patients with post-bronchodilation FEV1 less than 70 percent of predicted and a history of exacerbations, despite regular bronchodilator therapy.
• Respiforb 320 mcg + 9 mcg/dose: Indicated for asthma not adequately controlled with inhaled corticosteroids and short-acting β2-agonists, or adequately controlled with inhaled corticosteroids and long-acting β2-agonists; also for symptomatic therapy in COPD patients with post-bronchodilation FEV1 less than 70 percent of predicted and a history of exacerbations, despite regular bronchodilator therapy.

This medication is included in the List of Essential Medicines.